Back

Impact of allogenic Fecal Microbiota Transplantation (FMT) on lipid parameters in patients with metabolic syndrome (MetS): a meta-analysis

31 August 2024 (16:00 - 16:50)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering therapy: statins and beyond Biotherapies ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Leyi Wang

Peking University First Hospital, Beijing (China)

6 More presentations in this session

Presentation thumbnail
Plasma statin concentrations do not correlate with statin-induced myalgia
Doctor M. Ritvos (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
The high-dose statin treatment reduces neutrophil extracellular traps formation in patients with coronary artery disease
Doctor K. Stepien (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
Long-term administration of atorvastatin had no effect on the occurrence and progression of spontaneous hypertensive intracerebral hemorrhage in mice
Doctor X. Bian (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of inclisiran in real-world clinical practice. Results from the CHOLINET Registry
Doctor F. Marzano (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Efficacy of combination lipid lowering therapy in achieving low density lipoprotein cholesterol targets after one month of event in patients with acute coronary syndrome
Doctor K. Mahajan (Mandi, IN)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapy: statins and beyond

The Event

Event poster

ESC Congress 2024

31 August 2024 16:00 CET
You may be interested in
thumbnail
Congress Session
Liver and lipids in cardiometabolic syndrome
thumbnail
Congress Presentation
Gut Microbiota and Associated Metabolites Play a Key Role in the Pathogenesis of the Obesity Phenotype of Heart Failure With Preserved Ejection Fraction
thumbnail
Congress Presentation
Gut microbiota signatures in subclinical atherosclerosis: links to lipid metabolism and cardiovascular risk modulation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources